RETaliation - tackling rare resistance alterations to osimertinib

Matthew G. Krebs; Sanjay Popat

doi:10.1158/1078-0432.CCR-23-0993

RETaliation - tackling rare resistance alterations to osimertinib

Matthew G. Krebs, Sanjay Popat

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Commentary/debate › peer-review

Abstract

RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients. Inhibiting RET alongside osimertinib shows promising clinical activity but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.

Original language	English
Pages (from-to)	2951-2953
Number of pages	3
Journal	Clinical Cancer Research
Volume	29
Issue number	16
Early online date	14 Jun 2023
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-0993
Publication status	Published - 15 Aug 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-23-0993

Cite this

@article{033a575a6c1d42fbb5f6d266cdb293ad,

title = "RETaliation - tackling rare resistance alterations to osimertinib",

abstract = "RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients. Inhibiting RET alongside osimertinib shows promising clinical activity but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.",

author = "Krebs, {Matthew G.} and Sanjay Popat",

year = "2023",

month = aug,

day = "15",

doi = "10.1158/1078-0432.CCR-23-0993",

language = "English",

volume = "29",

pages = "2951--2953",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "16",

}

TY - JOUR

T1 - RETaliation - tackling rare resistance alterations to osimertinib

AU - Krebs, Matthew G.

AU - Popat, Sanjay

PY - 2023/8/15

Y1 - 2023/8/15

N2 - RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients. Inhibiting RET alongside osimertinib shows promising clinical activity but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.

AB - RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients. Inhibiting RET alongside osimertinib shows promising clinical activity but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.

U2 - 10.1158/1078-0432.CCR-23-0993

DO - 10.1158/1078-0432.CCR-23-0993

M3 - Commentary/debate

SN - 1078-0432

VL - 29

SP - 2951

EP - 2953

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 16

ER -

RETaliation - tackling rare resistance alterations to osimertinib

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this